Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Coronary Artery Disease: HELP
Articles by Daniel M. Kolansky
Based on 6 articles published since 2010
(Why 6 articles?)
||||

Between 2010 and 2020, Daniel M. Kolansky wrote the following 6 articles about Coronary Artery Disease.
 
+ Citations + Abstracts
1 Guideline SCAI expert consensus statement: 2016 best practices in the cardiac catheterization laboratory: (Endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologia intervencionista; Affirmation of value by the Canadian Association of interventional cardiology-Association canadienne de cardiologie d'intervention). 2016

Naidu, Srihari S / Aronow, Herbert D / Box, Lyndon C / Duffy, Peter L / Kolansky, Daniel M / Kupfer, Joel M / Latif, Faisal / Mulukutla, Suresh R / Rao, Sunil V / Swaminathan, Rajesh V / Blankenship, James C. ·Division of Cardiology, Winthrop University Hospital, Mineola, New York. ssnaidu@winthrop.org. · Warren Alpert Medical School of Brown University, Cardiovascular Institute, Providence, RI. · West Valley Medical Center, Caldwell, ID. · FirstHealth of the Carolinas, Pinehurst, NC. · Cardiovascular Medicine Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. · University of Illinois School of Medicine-Peoria, Peoria, IL. · University of Oklahoma and VA Medical Center, Oklahoma City, OK. · University of Pittsburgh and VA Pittsburgh Healthcare System, Pittsburgh, PA. · Duke University Medical Center, Durham, NC. · Weill Cornell Medical College, New York-Presbyterian Hospital, Greenberg Division of Cardiology, New York, NY. · Geisinger Medical Center, Danville, PA. ·Catheter Cardiovasc Interv · Pubmed #27137680.

ABSTRACT: -- No abstract --

2 Editorial SCAI position statement concerning coverage policies for percutaneous coronary interventions based on the appropriate use criteria. 2016

Klein, Lloyd W / Blankenship, James C / Kolansky, Daniel M / Dean, Larry S / Naidu, Srihari S / Chambers, Charles E / Duffy, Peter L / Anonymous2130861. ·Rush Medical College, Chicago, IL. · Geisinger Medical Center, Danville, PA. · University of Pennsylvania School of Medicine, Philadelphia, PA. · University of Washington, Seattle, WA. · Winthrop University Hospital, Mineola, NY. · Hershey Medical Center, Hershey, PA. · FirstHealth of the Carolinas, Reid Heart Center, Pinehurst, NC. ·Catheter Cardiovasc Interv · Pubmed #26968441.

ABSTRACT: -- No abstract --

3 Review Bioresorbable Scaffolds for Coronary Artery Disease. 2017

Nathan, Ashwin / Kobayashi, Taisei / Kolansky, Daniel M / Wilensky, Robert L / Giri, Jay. ·Cardiovascular Medicine Division, Hospital of the University of Pennsylvania, Perelman Center, South Tower, 11th Floor, 3400 Civic Center Boulevard, Philadelphia, PA, 19104, USA. · Penn Cardiovascular Outcomes, Quality, and Evaluative Research Center, Cardiovascular Institute, University of Pennsylvania, Philadelphia, PA, USA. · Cardiovascular Medicine Division, Hospital of the University of Pennsylvania, Perelman Center, South Tower, 11th Floor, 3400 Civic Center Boulevard, Philadelphia, PA, 19104, USA. Jay.Giri@uphs.upenn.edu. · Penn Cardiovascular Outcomes, Quality, and Evaluative Research Center, Cardiovascular Institute, University of Pennsylvania, Philadelphia, PA, USA. Jay.Giri@uphs.upenn.edu. ·Curr Cardiol Rep · Pubmed #28108898.

ABSTRACT: PURPOSE OF REVIEW: The purpose of this review is to present an overview of the recent evidence regarding the use of bioresorbable scaffolds in percutaneous coronary intervention. RECENT FINDINGS: Bioresorbable scaffolds represent a potentially unique engineering solution to the problems associated with metallic stents. The Absorb everolimus-eluting bioresorbable scaffold has been the most extensively tested of this class and is currently Food and Drug Administration-approved for use in the USA. While early studies suggested that it has comparable overall efficacy as compared to drug-eluting metallic stents, they also demonstrated a significantly increased risk of stent thrombosis. Bioresorbable scaffolds may be comparable to drug-eluting stents, though associated with an increased risk of stent thrombosis. They are a nascent technology with several competitive product designs in development and continued iterative technological improvements are expected over the next several years.

4 Article Accuracy of Fractional Flow Reserve Derived From Coronary Angiography. 2019

Fearon, William F / Achenbach, Stephan / Engstrom, Thomas / Assali, Abid / Shlofmitz, Richard / Jeremias, Allen / Fournier, Stephane / Kirtane, Ajay J / Kornowski, Ran / Greenberg, Gabriel / Jubeh, Rami / Kolansky, Daniel M / McAndrew, Thomas / Dressler, Ovidiu / Maehara, Akiko / Matsumura, Mitsuaki / Leon, Martin B / De Bruyne, Bernard / Anonymous821142. ·Division of Cardiovascular Medicine and Stanford Cardiovascular Institute, Stanford University School of Medicine, CA (W.F.F.). · Department of Cardiology, Friedrich-Alexander University Erlangen-Nürnberg, Germany (S.A.). · The Heart Center, Rigs Hospital, University of Copenhagen, Denmark (T.E.). · Department of Cardiology, Rabin Medical Center, Petach Tikva, Israel (A.A., R.K.). · Department of Cardiology, St. Francis Hospital, Roslyn, NY (R.S., A.J.). · Department of Cardiology, Cardiovascular Center Aalst OLV Hospital, Belgium (S.F., B.D.B.). · Columbia University Medical Center (A.J.K., A.M., M.B.L.), New York, NY. · Cardiovascular Research Foundation (A.J.K., A.M., M.B.L., T.M., O.D., M.M.), New York, NY. · Department of Cardiology, HaSharon Medical Center, Petach Tikva, Israel (G.G.). · Department of Cardiology, Shaare Zedek Medical Center, Jerusalem, Israel (R.J.). · Division of Cardiovascular Medicine, University of Pennsylvania School of Medicine, Philadelphia (D.M.K.). ·Circulation · Pubmed #30586699.

ABSTRACT: BACKGROUND: Measuring fractional flow reserve (FFR) with a pressure wire remains underutilized because of the invasiveness of guide wire placement or the need for a hyperemic stimulus. FFR derived from routine coronary angiography (FFR METHODS: Coronary angiography was performed in a routine fashion in patients with suspected coronary artery disease. FFR was measured in vessels with coronary lesions of varying severity using a coronary pressure wire and hyperemic stimulus. Based on angiograms of the respective arteries acquired in ≥2 different projections, on-site operators blinded to FFR then calculated FFR RESULTS: Ten centers in the United States, Europe, and Israel enrolled a total of 301 subjects and 319 vessels meeting inclusion/exclusion criteria which were included in the final analysis. The mean FFR was 0.81 and 43% of vessels had an FFR≤0.80. The per-vessel sensitivity and specificity were 94% (95% CI, 88% to 97%) and 91% (86% to 95%), respectively, both of which exceeded the prespecified performance goals. The diagnostic accuracy of FFR CONCLUSIONS: FFR CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique Identifier: NCT03226262.

5 Article Rationale and design of a randomized trial of automated hovering for post-myocardial infarction patients: The HeartStrong program. 2016

Troxel, Andrea B / Asch, David A / Mehta, Shivan J / Norton, Laurie / Taylor, Devon / Calderon, Tirza A / Lim, Raymond / Zhu, Jingsan / Kolansky, Daniel M / Drachman, Brian M / Volpp, Kevin G. ·University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. Electronic address: atroxel@mail.med.upenn.edu. · University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. ·Am Heart J · Pubmed #27595692.

ABSTRACT: BACKGROUND: Coronary artery disease is the single leading cause of death in the United States, and medications can significantly reduce the rate of repeat cardiovascular events and treatment procedures. Adherence to these medications, however, is very low. METHODS: HeartStrong is a national randomized trial offering 3 innovations. First, the intervention is built on concepts from behavioral economics that we expect to enhance its effectiveness. Second, the implementation of the trial takes advantage of new technology, including wireless pill bottles and remote feedback, to substantially automate procedures. Third, the trial's design includes an enhancement of the standard randomized clinical trial that allows rapid-cycle innovation and ongoing program enhancement. RESULTS: Using a system involving direct data feeds from 6 insurance partners followed by mail, telephone, and email contact, we enrolled 1,509 patients discharged from the hospital with acute myocardial infarction in a 2:1 ratio of intervention:usual care. The intervention period lasts 1 year; the primary outcome is time to first fatal or nonfatal acute vascular event or revascularization, including acute myocardial infarction, unstable angina, stroke, acute coronary syndrome admission, or death. CONCLUSIONS: Our randomized controlled trial of the HeartStrong program will provide an evaluation of a state-of-the-art behavioral economic intervention with a number of important pragmatic features. These include a tailored intervention responding to patient activity, streamlining of consent and implementation processes using new technologies, outcomes centrally important to patients, and the ability to implement rapid-cycle innovation.

6 Article Cardiac catheterization in patients with ascending aortic aneurysms: safety, success, and prevalence of coronary artery disease. 2014

Gertz, Zachary M / Levitt, Scott A / Epps, Kelly C / Bavaria, Joseph E / Moser, G William / Kolansky, Daniel M. ·Division of Cardiology, Virginia Commonwealth University Medical Center, 1200 East Broad St, West Hospital, 5th Floor, West Wing, Room 529-B, Richmond, VA 23298 USA. zgertz@mcvh-vcu.edu. ·J Invasive Cardiol · Pubmed #24907078.

ABSTRACT: BACKGROUND: Evaluation for coronary artery disease (CAD) is recommended prior to surgery for ascending aortic aneurysms. Concerns regarding the use of coronary angiography in this population include safety and the ability to successfully selectively engage the coronary arteries. Additionally, the prevalence of CAD is not well described. METHODS: We retrospectively reviewed all patients referred for cardiac catheterization prior to elective surgery for an ascending aortic aneurysm at our institution over a 4-year period. Catheter selection was based on knowledge of the aneurysm size. Images were screened for whether selective coronary engagement was achieved and for the presence of significant coronary disease. RESULTS: A total of 205 patients met the inclusion criteria. The mean age was 61 years and 63% were male. There were no adverse events related to catheterization. The left coronary artery was selectively engaged in 98% of patients, and the right coronary in 92%. On average, 3.1 catheters were used for angiography per patient. Coronary artery disease was present in 19% of patients (n = 39). Increasing age was the only risk factor significantly associated with the presence of disease. Coronary bypass was required in 15% of patients at the time of aortic aneurysm surgery. CONCLUSIONS: Coronary angiography can be performed safely and the coronary arteries can be successfully selectively engaged in patients with ascending aortic aneurysms. The findings frequently impact the surgical approach. We believe that coronary angiography should be part of the routine preoperative evaluation in appropriate patients.